Syncona Limited - Strategy Update
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
Syncona Limited
("Syncona" or the "Company")
Strategy update
Proposed change to investment objective and policy to maximise value for shareholders over the medium term
Exploring options to provide shareholders with accelerated cash returns
Seeking to offer certain shareholders opportunity to roll interests into a new independent private fund managed by SIML
Syncona's Board of Directors (the "Board") has, in consultation with the Company's investment manager, Syncona Investment Management Limited ("SIML"), and advisers, undertaken a comprehensive review of options to maximise value for shareholders.
As part of this review, the Board has engaged extensively with shareholders, who expressed a range of perspectives, reflecting Syncona's diverse shareholder register.
The review follows a period of underperformance for the biotech sector with the S&P Biotechnology Index still 52.0%[1] below its peak in
Over this period, the SIML team has rebalanced the portfolio, prioritising capital towards the most promising assets. Whilst the Board believes SIML has made significant steps in driving portfolio companies to late-stage and clinical development, where there is the potential to deliver strong risk-adjusted returns over the medium term, it has also listened to the broad range of shareholder views and will, in the near term, seek shareholder approval for a change to the Company's investment objective and policy.
Proposed change to investment objective and policy and capital allocation policy to maximise value over the medium term
The Board intends, subject to approval by the Financial Conduct Authority (the "FCA"), to propose to its shareholders a change to the Company's investment objective and policy to move to an orderly realisation of its portfolio assets, with a view to achieving a balance between returning cash to shareholders in a timely manner and maximising value.
Alongside the proposed new investment objective and policy, the Board also intends to adopt a new capital allocation policy. This will seek to continue financial support to existing portfolio companies, which have the potential to provide liquidity via M&A or the public markets, to deliver their identified key value inflection points, and additionally to preserve portfolio company value in third-party financings.
It is the Board's intention that net proceeds from any disposal of interests in private portfolio companies will be returned to shareholders, subject to retaining a prudent reserve for operating costs. Any general meeting to approve the proposed change of the Company's investment objective and policy will take place once the Board has certainty on whether an acceleration of cash returns to shareholders will be achievable (see below).
Maximising value for shareholders over the medium term
If approved, the Board intends that the Company's new investment objective and policy will be reviewed by the Board once significant proceeds have been returned to shareholders or after three years to ensure the continued return of net proceeds from realisations remains in the best interests of shareholders. Any amendment to the Company's investment objective and policy at that point would require further FCA and shareholder approval.
Potential acceleration of cash returns to shareholders
In conjunction with the proposed investment objective and policy changes, the Company is also exploring options to accelerate realisations, which may include a sale of a small portion of its interests in certain of its portfolio companies at a modest implied premium to the current share price and at a discount to NAV. If the Company was able to achieve any such realisations, it would seek to return the net proceeds to shareholders, together with the cash the Company has currently allocated to support future investments into any divested assets.
Subject to shareholder approval of a new investment objective and policy, it will be the Board's intention to seek to accelerate cash returns in light of the Company's new strategy, even in the absence of near-term realisations.
Seeking to find alternative opportunities for shareholders who wish to continue to have exposure to early-stage companies
The Board recognises that certain shareholders may wish to continue to have exposure to new and early-stage life science companies. As such, the Board is exploring the possibility of providing institutional shareholders with an opportunity to roll their interests in the Company into a new private investment vehicle ("New Fund") independent of the Company. Discussions are ongoing with a number of sophisticated institutional and strategic investors and
The New Fund's strategy would be to build world-class companies from ground-breaking science or technology sourced from the LRPs and elsewhere. The New Fund would be managed by SIML, harnessing its expertise and track record. In such circumstances, SIML may be separated from the Syncona Group to enable it to manage both the portfolio of the Company and the New Fund.
If the New Fund is successful in raising sufficient capital, the Company would seek to enter into the sale of a small portion of its interests in certain of its portfolio companies to the New Fund. There can be no certainty that new capital will be raised or any sale will occur.
Suspension of 2032 targets
As a consequence of the proposed change in investment objective and policy, the Board would, following guidance from SIML, seek to suspend its previously published 2032 targets, including the ambition to grow assets to
Board changes
In the event the new investment objective and policy are approved by shareholders, the Company would expect to reduce the size of the Board to reflect the Company's strategy.
The Company will keep the market updated on progress of the new strategy as and when appropriate.
The person responsible for making this announcement on behalf of the Company is
Enquiries
Syncona Limited
Tel: +44 (0) 20 3981 7940
FTI Consulting
Tel: +44 (0) 20 3727 1000
IMPORTANT NOTICES
This announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities.
Certain statements contained in this announcement constitute "forward-looking statements" with respect to the results, financial condition, performance, developments or achievements of Syncona and its subsidiaries. Words such as "believes", "anticipates", "estimates", "expects", "intends", "plans", "aims", "potential", "will", "would", "could", "considered", "likely", "estimate" and variations of these words and similar future or conditional expressions, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. These statements and forecasts are inherently predictive, speculative and involve risks and uncertainties and assumptions that could cause actual results, financial condition, performance, developments or achievements to differ materially from those expressed or implied by these forward-looking statements and forecasts. Many of these risks, uncertainties and assumptions relate to factors that are beyond Syncona's ability to control, predict or estimate precisely. No representation or warranty is made, and no responsibility or liability is accepted, as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements. The forward-looking statements contained in this announcement speak only as of the date of this announcement. Syncona expressly disclaims any obligation or undertaking to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required to do so by applicable law or regulation, the FCA or London Stock Exchange plc.
No statement in this announcement is intended to be a profit forecast or profit estimate for any period, and no statement in this announcement should be interpreted to mean that earnings, earnings per share or income, cash flow from operations or free cash flow for Syncona for the current or future financial years would necessarily match or exceed the historical published earnings, earnings per share or income, cash flow from operations or free cash flow for Syncona.
Neither the content of Syncona's website (or any other website) nor the content of any website accessible from hyperlinks on Syncona's website (or any other website) is incorporated into or forms part of this announcement.
This announcement has been prepared for the purposes of complying with applicable law and regulation in the
[1] As at
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE